Skip to main content
OpenTrials
Completed

NCT Number: NCT02472457

Crohn Disease Exclusion Diet After Single Medication De-escalation

The primary objective of this study is to determine whether pediatric Crohn Disease (CD) patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer time-to-relapse as opposed to those on an unrestricted diet.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States

About this study

Crohn disease (CD) is an idiopathic, chronic, relapsing and remitting inflammatory condition of the gastrointestinal tract with a high risk for complications and need for surgical interventions, particularly in children. Immunomodulators and biologic therapies are effective at inducing and maintaining remission in pediatric CD, yet there is no proven strategy for reducing exposure to medications once sustained remission has been achieved. Diet has been proven to impact disease activity in CD and may allow for sustained drug-free remission. The primary objective of this study is to determine whether pediatric CD patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet (CDED). The hypothesis is that subjects on the CDED will have longer time-to-relapse as opposed to those on an unrestricted diet.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a diagnosis of Crohn Disease using the Revised Porto criteria who will be withdrawing from biologic or immunomodulator monotherapy as part of clinical care.
  • Normal Growth Velocity, or Tanner 5
  • Steroid-free Remission (Pediatric Crohn Disease Activity Index Score <10 without the height component) for at least 12 months prior to enrollment
  • Colonoscopy during the preceding 3 months with complete mucosal healing or only few aphthous ulcerations located in one segment
  • Stool calprotectin <250µg/g during the preceding 3 months
  • Parental/guardian permission (informed consent) and, if appropriate, child assent.

Exclusion criteria

  • Discontinuation of biologic or immunomodulator therapy by the subject without the approval of the primary gastroenterologist.
  • Those subjects who in the judgment of the investigative team are unable to complete the study endpoints.

Treatment and study plan

Crohn Disease Exclusion Diet

Other

The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.

free diet

Other

This diet contains no restrictions.

Other names: Placebo

Primary outcomes

  1. Sustained Relapse-free Remission

    Time frame: At 52 weeks following enrollment

    Remission defined by the Pediatric Crohn Disease Activity Index, C-reactive protein, and stool calprotectin

Secondary outcomes

  1. Time-to-relapse

    Time frame: Up to 104 weeks

    Remission defined by the Pediatric Crohn Disease Activity Index, C-reactive protein, and stool calprotectin

  2. Microbial Composition of Gastrointestinal Tract (Types and Quantities of Microorganisms)

    Time frame: 6 weeks

    Change in the microbial composition of the stool, mouth and rectum from baseline to 6 weeks

  3. Microbial Composition of Gastrointestinal Tract (Types and Quantities of Microorganisms)

    Time frame: 52 weeks

    Change in the microbial composition of the stool, mouth and rectum from baseline to 52 weeks

Other outcomes

  1. Dietary Compliance

    Time frame: Up to 52 weeks

    Using modified Medication Adherence Rating Scale (MARS) questionnaire

Sponsors and collaborators

Lead sponsor

Children's Hospital of Philadelphia

Other

Collaborators

  • Wolfson Medical Center

Registry information

Official study title

Biologic and Immunomodulator Withdrawal in Pediatric Crohn Disease With Deep Clinical Remission Using the Crohn Disease Exclusion Diet

Acronym: CEASE

Important dates

Study start
2015
Primary completion
2019
Study completion
2020
First posted
Jun 15, 2015
Registry last updated
Oct 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.